/////////////
Drug discovery is broken.
Katamaran is fixing it.
Combining patient derived tumoroids, automation, and generative AI design, Katamaran’s AI powered super engine revives dormant science to create life saving cancer drugs faster and for more people.
Developing a single therapy can take a decade and billions of dollars, slowed by outdated cell line and animal models, along with narrowly focused trials that overlook much of the world’s genetic diversity.
Cancer still claims 10 million lives every year, while thousands of promising molecules gather dust.
By accelerating discovery and broadening access, we transform hidden potential into therapies that reach everyone, everywhere.
By the numbers
50,000,000+
people worldwide are living with cancer today
9700+
deaths every year-roughly one in six global deaths
18
lives lost every minute.
10-
12
years to bring drug to the market
200K vs. $
$
60K
per year advanced drug costs:
(Developed nations vs India)
95%
35,000,000+
Cases per year projected by 2036
Oncology drug candidates fail in clinical trials
Our Solution
Precision medicine, powered by human relevant data
Katamaran integrates generative AI, patient derived tumoroids lab grown, 3D mini tumors from real patient tumors and robotic automation labs to leapfrog guess and wait oncology R&D. We design, test, and iterate directly on human biology from day one, dramatically reducing timelines and costs so breakthrough cancer therapies reach patients faster.
70%
cost reduction
6x
faster lead development
2x
higher success odds
Predict
Generative models forecast the best-fit targets
Validate
Tumoroids confirm human relevance
Scale
Robotics automation compress months of lab work into days
*Modeled against conventional workflows; based on internal data and published benchmarks.
Our R&D and Pipeline
//////////////
Company and Team
Arun Asaithambi, Ph.D.
Founder
Anand Asaithambi,
Co-Founder
“Our platform is engineered to cut development costs by up to two-thirds, accelerate lead selection six fold, and because we validate on patient-derived tumoroids double the odds a therapy reaches the clinic.”
- Arun Asaithambi, Ph.D. Founder
+
+
+
//////////////
Research Labs
//////////////
Featured News
April 9, 2024
October 10, 2017
Aug 1, 2025
For more news
What Experts Are Saying
“Head and neck cancers are extremely common but low awareness and non-specific symptoms delay diagnosis. When caught early they have excellent cure rates. Precision therapies are becoming more crucial as a one size fits all approach is ineffective.”
-Dr. Narayana Subramaniam
Lead Consultant, Head & Neck Oncology, Aster Hospitals, Bangalore
+
+
+
//////////////
We’re looking for collaborators, investors, and visionary scientists. Reach out and be part of the mission.
Quick Links
Our Address
India :
Unit, #603, 6th floor, Sigmasoft tech park, Gamma block, Whitefeild, Bengaluru, Karnataka, 560066
US :
Unit 419,180 talmadge rd, Edison nj 08817
UK :
41 Clooney Terrace, Londonderry, Northern Ireland, BT47 6AP
Follows us
© 2025 Katamaran Industries. Innovating for global health equity.
